Mergers & Acquisitions ·
Supernus Pharmaceuticals announced a proposed merger of equals with Indivior on August 3, 2026
SUPNSupernus, Inc.
Supernus Pharmaceuticals announced a proposed merger of equals with Indivior on August 3, 2026. The transaction is structured as a 100% tax-free stock-for-stock exchange where Supernus shareholders will receive 1.5401 Indivior shares for each share held. Prior to closing, Indivior intends to declare an aggregate special cash dividend of $1 billion to its pre-closing stockholders. The combined entity is projected to generate approximately $2.2 billion in pro forma net revenues and achieve at least $125 million in annual cost synergies. Supernus shareholders are expected to hold 43.5% ownership, with Jack Khattar serving as CEO of the new company headquartered in Rockville, Maryland. The deal targets a Q4 2026 closing subject to shareholder and regulatory approvals. Supernus Pharmaceuticals operates in the biopharmaceutical industry, developing and commercializing treatments for central nervous system disorders.